What Mutabilis does

Mutabilis, now operating as Tamrisa, is a French specialty pharmaceutical venture headquartered in Paris with an R&D site at Parc Biocitech in Romainville. Founded in 2001, the company is dedicated to tackling anti-microbial resistance (AMR) along three pillars: innovation, stewardship, and access. Its commercial arm supplies a portfolio of eight long-established, branded antibiotics — including Rovamycine (spiramycin), Oflocet/Monoflocet/Tarivid (ofloxacin), Secnidal (secnidazole), Benambax/Pentacarinat (pentamidine), Triacefan (ceftriaxone), Cefepime Tamrisa, Imipenem Cilastatine Tamrisa, and Meropenem Tamrisa — registered and sold in more than 40 countries through a network of distribution partners and manufacturing counterparties.

Its innovation engine centers on dabocins, a proprietary new class of antibacterials built on the diazabicyclooctane scaffold that uniquely combines Penicillin-Binding Protein inhibition with stability against all four β-lactamase classes (A, B, C, D). Two active programs — TMR010 (formerly EBL-1463) targeting carbapenem-resistant Enterobacterales, and TMR020 targeting carbapenem-resistant Enterobacterales, Pseudomonas and Acinetobacter — are advancing through Lead Optimization/Preclinical/Phase 1 with support from CARB-X, the Novo Holdings REPAIR Impact Fund, and Roche.

The company is co-led by Wandrille Ract-Madoux and Benoît Hennion, with François Moreau serving as Scientific Director. It is privately held, funded by management, industry partners and private shareholders, and employs 11-50 people. The business model blends (i) one-time product/distribution sales of established antibiotics across 40+ countries and (ii) long-cycle R&D, with future licensing/royalty economics dependent on clinical progression of the dabocin pipeline.

Name

Mutabilis

Legal name

Tamrisa

Website

https://mutabilis.fr

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Mutabilis (operating as Tamrisa) is a French specialty pharma company that combats anti-microbial resistance by commercializing eight established branded antibiotics in 40+ countries and developing dabocins, a proprietary new class of antibacterials, with two preclinical/Phase 1 programs targeting carbapenem-resistant Gram-negative infections.

Ownership category

akta.pro rank

Product category

Anti-infective Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Anti-infective drug discovery
• Anti-microbial resistance
• Antibiotic pharmaceutical
• Dabocin antibacterial development
• Generic antibiotic distribution

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Antibiotic product sales: Tamrisa commercializes a portfolio of eight proven antibiotics registered and sold in more than 40 countries through a network of distribution partners. Revenue is generated through product sales of established antibiotics including macrolides, fluoroquinolones, cephalosporins, and carbapenems.
2. R&D program development: The company develops novel antibiotic candidates (TMR010 and TMR020) for carbapenem-resistant bacterial infections with support from funding partners CARB-X, Novo Holdings REPAIR Impact Fund, and Roche, potentially generating future revenue through licensing or commercialization of new drug candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Mutabilis (operating as Tamrisa) is a specialized pharmaceutical venture that discovers and develops novel anti-infective drug classes, specifically dabocins targeting carbapenem-resistant Gram-negative infections, while commercializing a portfolio of eight established branded antibiotics across more than 40 countries through distribution partners. The company runs two R&D pipeline programs (TMR010 and TMR020) in preclinical/Phase 1 stages with the support of CARB-X, Novo Holdings REPAIR Impact Fund, and Roche.

Product overview

Mutabilis (operating as Tamrisa) is a specialized pharmaceutical company focused on tackling anti-microbial resistance through innovation, stewardship, and access. The company operates a dual-track model combining a commercial portfolio of established antibiotics with a novel R&D pipeline. The commercial portfolio includes eight branded antibiotics—Rovamycine® (spiramycin), Oflocet®/Monoflocet®/Tarivid® (ofloxacin), Secnidal® (secnidazole), Benambax®/Pentacarinat® (pentamidine isetionate), Triacefan® (ceftriaxone), Cefepime Tamrisa® (cefepime), Imipenem Cilastatine Tamrisa® (imipenem cilastatine), and Meropenem Tamrisa® (meropenem)—registered and commercialized in over 40 countries. The R&D pipeline centers on dabocins, a new class of antibacterials derived from the diazabicyclooctane scaffold, with two active programs (TMR010 and TMR020) in preclinical/Phase 1 development targeting carbapenem-resistant Gram-negative bacterial infections.

Differentiator

Problem solved

Functional benefit

Brands

• Rovamycine: Macrolide antibiotic (spiramycine) used for bacterial infections including respiratory tract infections and toxoplasmosis prevention.
• Oflocet / Monoflocet / Tarivid
• Secnidal
• Benambax / Pentacarinat
• Triacefan
• Cefepime Tamrisa
• Imipenem Cilastatine Tamrisa
• Meropenem Tamrisa

Products and services

• Rovamycine (spiramycin)
• Oflocet / Monoflocet / Tarivid (ofloxacin)
• Secnidal (secnidazole)
• Benambax / Pentacarinat (pentamidine isetionate)
• Triacefan (ceftriaxone)
• Cefepime Tamrisa (cefepime)
• Imipenem Cilastatine Tamrisa (imipenem cilastatine)
• Meropenem Tamrisa (meropenem)
• TMR010 (i.v.)
• TMR020 (i.v.)

Quantifiable outcome

• Products registered and commercialized in 40+ countries through distribution partners
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Manufacturing partnerssupportingOthersManufacturing partners support the production and supply chain security for the company's portfolio of eight proven antibiotics distributed in 40+ countries.

Scale indicators3 records

Recent moves2 records

Expansion highlights5 records

Direct peers

• Iterum Therapeutics: Iterum is a clinical-stage anti-infectives company developing oral and IV antibiotics against multi-drug resistant pathogens including carbapenem-resistant Enterobacterales, directly comparable to Tamrisa's TMR010/TMR020 programs.
• Entasis Therapeutics (Innoviva): Entasis develops targeted antibacterial therapies for serious drug-resistant infections, including carbapenem-resistant Acinetobacter — overlapping directly with Tamrisa's pipeline focus on WHO priority pathogens.
• Nabriva Therapeutics: Nabriva is a biopharmaceutical company commercializing antibiotics (lefamulin) and developing new anti-infectives, sharing Tamrisa's hybrid model of marketed antibiotics plus innovative R&D pipeline.
• Melinta Therapeutics: Melinta is an antibiotics-focused commercial-stage company with a marketed portfolio of branded antibacterials, mirroring Tamrisa's strategy of coupling established antibiotic sales with stewardship commitments.
• Paratek Pharmaceuticals: Paratek developed and commercialized tetracycline-class antibiotics (omadacycline, sarecycline) for serious community-acquired infections, a comparable small-cap anti-infectives commercial and R&D story.
• Tetraphase Pharmaceuticals: Tetraphase developed eravacycline for complicated intra-abdominal and urinary tract infections, an antibiotic specialist with comparable scientific depth and AMR focus before its acquisition by La Jolla.
• VenatoRx Pharmaceuticals: VenatoRx develops novel antibacterial agents, including β-lactam/β-lactamase inhibitor combinations targeting resistant Gram-negative infections, directly overlapping Tamrisa's dabocin scaffold work.
• Achaogen (historical): Achaogen developed plazomicin for carbapenem-resistant Enterobacterales, providing a directly comparable commercial-stage AMR antibiotics story before its wind-down.

Broad incumbents

• Roche: Roche is a global pharmaceutical incumbent that actively backs Tamrisa's pipeline and historically has broader anti-infectives and diagnostic interests relevant to AMR stewardship.
• GSK: GSK operates one of the largest anti-infectives franchises globally and pursues novel antibacterial R&D, representing the large-cap comparable for Tamrisa's commercial portfolio and AMR pipeline ambition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mutabilis

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mutabilis